Has Alpine Immune Sciences Found the Deal of a Lifetime?

Health and Healthcare

Published: June 18, 2020 10:21 am

Alpine Immune Sciences Inc. (NASDAQ: ALPN) shares doubled on Thursday after the company announced a license agreement with AbbVie Inc. (NYSE: ABBV) for its ALPN-101 dual CD28/ICOS costimulation antagonist.

Under the terms of the agreement, Alpine will receive an upfront payment of $60 million and also will be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones.

Note that prior to this move, Alpine Immune Sciences only had a market cap near $90 million.

Additionally, Alpine is eligible to receive tiered royalties on net sales of ALPN-101. In exchange, AbbVie will receive an option to an exclusive license for ALPN-101.

During this option period, Alpine will conduct a phase 2 study in systemic lupus erythematosus. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for ALPN-101.

Note that ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways, which play a big role in multiple autoimmune and inflammatory diseases. Lupus is an example of one of the major diseases that APLN-101 looks to treat.

So far, favorable safety and tolerability, pharmacokinetics and pharmacodynamics have been observed in a first-in-human study in adult healthy volunteers for ALPN-101.

Alpine Immune Sciences stock traded up about 100% early Thursday to $9.74, in a 52-week range of $2.05 to $15.00. The consensus price target is $11.75.

AbbVie stock was relatively flat, at $95.67 in a 52-week range of $62.55 to $99.35. The consensus price target is $100.81.

ALSO READ: RBC’s Top 2020 ESG Best Idea Stocks to Buy

In 20 Years, I Haven’t Seen A Cash Back Card This Good

After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.

A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.

Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.